Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
EYES

EYES - Second Sight Medical Products Inc Stock Price, Fair Value and News

2.00USD0.00 (0.00%)Market Closed

Market Summary

EYES
USD2.000.00
Market Closed
0.00%

EYES Stock Price

View Fullscreen

EYES RSI Chart

EYES Valuation

Market Cap

110.0M

Price/Earnings (Trailing)

-4.33

Price/Sales (Trailing)

214.13

Price/Free Cashflow

-4.94

EYES Price/Sales (Trailing)

EYES Profitability

Operating Margin

-877.98%

Return on Equity

-88.38%

Return on Assets

-47.17%

Free Cashflow Yield

-20.26%

EYES Fundamentals

EYES Revenue

Revenue (TTM)

475.0K

EYES Earnings

Earnings (TTM)

-25.4M

Earnings Growth (Yr)

4.42%

Earnings Growth (Qtr)

-0.22%

Breaking Down EYES Revenue

Last 7 days

11.1%

Last 30 days

8.7%

Last 90 days

85.2%

How does EYES drawdown profile look like?

EYES Financial Health

Current Ratio

5.13

EYES Investor Care

Shares Dilution (1Y)

8.24%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2022512.5K00475.0K
2021149.5K283.0K416.5K550.0K
20202.3M1.1M016.0K
20197.0M6.4M4.6M3.4M
20187.9M7.6M8.2M6.9M
20173.9M5.1M5.6M8.0M
20168.3M6.7M5.6M4.0M
20154.4M6.5M8.1M8.9M
20142.0M2.5M2.9M3.4M
20130001.6M

Tracking the Latest Insider Buys and Sells of Second Sight Medical Products Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 14, 2022
williams gregg
bought
200
2.00
100
-
Jun 13, 2022
williams gregg
bought
7,400
2.00
3,700
-
Jun 03, 2022
williams gregg
bought
9,748
2.4617
3,960
-
Jun 02, 2022
williams gregg
bought
245,722
2.3366
105,162
-
Jun 01, 2022
williams gregg
bought
299,282
2.2594
132,461
-
May 31, 2022
williams gregg
bought
174,447
2.33
74,870
-
May 24, 2022
williams gregg
bought
110,028
1.9847
55,438
-
May 23, 2022
williams gregg
bought
328,570
1.9656
167,160
-
May 20, 2022
williams gregg
bought
589,548
1.9163
307,649
-
May 19, 2022
williams gregg
bought
196,362
1.8049
108,794
-

1–10 of 50

Which funds bought or sold EYES recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Sep 09, 2022
B. Riley Wealth Management, Inc.
new
-
20.00
20.00
-%
Nov 04, 2021
BBVA USA
sold off
-100
-22,000
-
-%

1–2 of 2

Are Funds Buying or Selling EYES?

Are funds buying EYES calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EYES
No. of Funds

Unveiling Second Sight Medical Products Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 02, 2023
williams gregg
38.9%
23,597,129
SC 13D/A
Apr 25, 2023
bolck joachim eberhard
11.03%
5,597,123
SC 13D
Sep 02, 2022
williams gregg
41.22%
20,909,620
SC 13D/A
Sep 01, 2022
mendelsohn adam
7.51%
3,712,573
SC 13D
Jul 22, 2022
williams gregg
38.06%
172,926,799
SC 13D/A
Jan 13, 2022
empery asset management, lp
0.00%
0
SC 13G/A
Jun 28, 2021
empery asset management, lp
8.71%
3,300,000
SC 13G
Feb 11, 2021
altium capital management lp
-
0
SC 13G/A
Jan 20, 2021
empery asset management, lp
0.00%
0
SC 13G/A
Jan 08, 2021
pixium vision, s.a.
30.1%
6,978,886
SC 13D

Recent SEC filings of Second Sight Medical Products Inc

View All Filings
Date Filed Form Type Document
May 14, 2024
4
Insider Trading
May 14, 2024
4
Insider Trading
May 14, 2024
4
Insider Trading
May 14, 2024
4
Insider Trading
May 14, 2024
4
Insider Trading
May 13, 2024
10-Q
Quarterly Report
May 13, 2024
8-K
Current Report
May 03, 2024
EFFECT
EFFECT
May 02, 2024
S-3/A
S-3/A
Apr 29, 2024
ARS
ARS

Second Sight Medical Products Inc News

Latest updates
Yahoo Lifestyle UK • 14 May 2024 • 08:48 pm
Yahoo Movies UK • 13 May 2024 • 05:49 pm
Drug Delivery Business News • 20 months ago

Second Sight Medical Products Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q12021Q42021Q32021Q22021Q12020Q42020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q22018Q12017Q42017Q32017Q22017Q1
Revenue--------16.002574974721,2821,1281,7672,2461,9079763,1091,6102,2361,009
Gross Profit---130---500--3731083493971674621,0713081,247609-1,109-118
Operating Expenses99.6%7,7973,9074,1243,4852,2962,8431,7743,1168,9048,4997,7278,79010,1659,0449,0089,059-----
  S&GA Expenses174.3%3,3691,228-7666171,3382,472-1,2891,5167011,0011,3081,6892,1032,4063,0402,8793,011----
  R&D Expenses65.3%4,4282,6795,0402,8686953343473233,8874,1453,3793,4362,1832,4382,6722,422-----
Net Income-85.6%-7,284-3,924-1,283-3,491-2,675-2,988-1,291-3,100-8,886-7,868-7,584-8,440-9,700-8,858-8,522-7,961-----
Net Income Margin-31.8%-29.24*-22.19*-18.98*-25.08*-30.24*-60.08*---------------
Free Cashflow-65.1%-5,292-3,206-3,215-3,029-4,185-778---------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets17.4%54.0046.0053.0060.0045.0051.0057.0066.0069.0071.0074.0076.0028.004.004.005.004.0017.0024.0032.0039.00
  Current Assets36.6%32.0023.0031.0036.0041.0048.0054.0057.0060.002.0073.0075.0028.004.003.005.004.0013.0020.0028.0035.00
    Cash Equivalents43.5%30.0021.0025.0032.0038.0045.0052.0056.0060.002.001.0074.0027.002.002.004.002.0011.0018.0025.0032.00
  Inventory------------------1.001.001.002.00
  Net PPE-2.3%2.002.001.001.001.001.001.000.000.001.000.000.000.000.000.000.000.001.001.001.001.00
Liabilities0.2%25.0025.0027.0027.006.007.006.003.002.003.004.004.007.005.003.003.005.009.0010.0010.0010.00
  Current Liabilities7.3%6.006.007.007.006.007.006.003.002.002.004.004.007.005.003.003.005.007.007.008.007.00
Shareholder's Equity38.3%29.0021.0026.0032.0038.0044.0051.0063.0066.002.001.001.002.002.001.002.00-7.0014.0021.0029.00
  Retained Earnings-6.1%-104-98.44-92.41-85.63-79.10-72.79-65.50-333-330-58.90-327-324-322-319-318-316-313-304-296-289-280
  Additional Paid-In Capital11.8%1331191191188.001178.0049.0049.007.0049.0049.0049.0049.0049.0049.0049.0049.0048.0047.0047.00
Shares Outstanding-55.00---51.00---13.0037.008.0013.009.00-7.008.00-----
Float----39.00---57.00---146---13.00---33.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-29.6%-4,512-3,481-7,702-5,550-6,966-5,203-6,959-3,449-3,176-2,959-3,029-4,185-778-1,453-1,478-5,237-8,654-7,386-6,458-6,635-7,150
  Share Based Compensation-23.3%35346051152436936139213.0034083839019.0019.0027.0027.0088.00279482686859898
Cashflow From Investing75.5%-182-743-63.00-44.00-37.00-41.00-181-86.00-30.00-256---1.00398--331-99.00-230-127-37.00
Cashflow From Financing59421.7%13,69023.001037.00--55,37712.008,0014,217-68,21151,14824,4662,200-6,403-5.00352-23834,399
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EYES Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development, net of grants$ 3,726$ 3,955
General and administrative, net of grants2,5012,646
Total operating expenses6,2276,601
Loss from operations(6,227)(6,601)
Other income, net188283
Net loss$ (6,039)$ (6,318)
Net loss per common share - basic and diluted(0.12)(0.12)
Weighted average common shares outstanding - basic and diluted52,20250,755

EYES Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 29,648$ 20,654
Prepaid expenses and other current assets1,8542,408
Total current assets31,50223,062
Property and equipment, net1,6891,729
Right-of-use assets19,21219,616
Restricted cash1,3381,338
Other assets4752
Total assets53,78845,797
Current liabilities:  
Accounts payable570542
Accrued expenses1,9531,727
Litigation accrual1,6751,675
Accrued compensation expense506396
Current operating lease liabilities1,4341,383
Total current liabilities6,1385,723
Long-term operating lease liabilities18,94019,313
Total liabilities25,07825,036
Stockholders’ equity:  
Preferred stock, par value $0.0001 per share; 10,000 shares authorized; none outstanding
Common stock, par value $0.0001 per share; 300,000 shares authorized; shares issued and outstanding: 54,978 and 51,031 at March 31, 2024 and December 31, 2023, respectively55
Additional paid-in capital133,094119,054
Accumulated other comprehensive income88140
Accumulated deficit(104,477)(98,438)
Total stockholders’ equity28,71020,761
Total liabilities and stockholders’ equity$ 53,788$ 45,797
EYES
0
 WEBSITEsecondsight.com

Second Sight Medical Products Inc Frequently Asked Questions


What is the ticker symbol for Second Sight Medical Products Inc? What does EYES stand for in stocks?

EYES is the stock ticker symbol of Second Sight Medical Products Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Second Sight Medical Products Inc (EYES)?

As of Fri May 17 2024, market cap of Second Sight Medical Products Inc is 109.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EYES stock?

You can check EYES's fair value in chart for subscribers.

What is the fair value of EYES stock?

You can check EYES's fair value in chart for subscribers. The fair value of Second Sight Medical Products Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Second Sight Medical Products Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EYES so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Second Sight Medical Products Inc a good stock to buy?

The fair value guage provides a quick view whether EYES is over valued or under valued. Whether Second Sight Medical Products Inc is cheap or expensive depends on the assumptions which impact Second Sight Medical Products Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EYES.

What is Second Sight Medical Products Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EYES's PE ratio (Price to Earnings) is -4.33 and Price to Sales (PS) ratio is 214.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYES PE ratio will change depending on the future growth rate expectations of investors.